Dulaglutide: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
Created page with "{{Short description|Diabetes medication}} {{Infobox drug | image = Autoinjector with Trulicity by Lilly (Dulaglutid)-3129.jpg | width = | alt = Autoinjector with Trulicity by Lilly | caption = <!-- Clinical data --> | pronounce = | tradename = Trulicity, others | Drugs.com = {{Drugs.com|monograph|dulaglutide}} | MedlinePlus = a614047 | DailyMedID = Dulaglutide | pregnancy_AU..."
 
Marked this version for translation
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
<languages />
<translate>
<!--T:1-->
{{Drug List/ja|state6=uncollapsed}}
{{Pathnav|Medication|Diabetes medication|GLP-1 receptor agonist|frame=1}}
{{Short description|Diabetes medication}}
{{Short description|Diabetes medication}}
{{Infobox drug
{{Infobox drug
Line 6: Line 11:
| caption            =
| caption            =


<!--T:2-->
<!-- Clinical data -->
<!-- Clinical data -->
| pronounce          =  
| pronounce          =  
Line 22: Line 28:
| ATC_supplemental  =
| ATC_supplemental  =


<!--T:3-->
<!-- Legal status -->
<!-- Legal status -->
| legal_AU          = S4
| legal_AU          = S4
Line 43: Line 50:
| legal_status      = <!--For countries not listed above-->
| legal_status      = <!--For countries not listed above-->


<!--T:4-->
<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->
| bioavailability    =  
| bioavailability    =  
Line 53: Line 61:
| excretion          =
| excretion          =


<!--T:5-->
<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number_Ref    =  
| CAS_number_Ref    =  
Line 76: Line 85:
| synonyms          =
| synonyms          =


<!--T:6-->
<!-- Chemical and physical data -->
<!-- Chemical and physical data -->
| IUPAC_name        =  
| IUPAC_name        =  
Line 99: Line 109:
}}
}}


<!--T:7-->
<!-- Definition and medical sues -->
<!-- Definition and medical sues -->
'''Dulaglutide''', sold under the brand name '''Trulicity''' among others, is a [[medication]] used for the treatment of [[type 2 diabetes]] in combination with diet and exercise. It is also approved in the United States for the reduction of [[major adverse cardiovascular events]] in adults with type 2 diabetes who have established [[cardiovascular disease]] or multiple cardiovascular risk factors. It is a once-weekly injection.
'''Dulaglutide''', sold under the brand name '''Trulicity''' among others, is a [[medication]] used for the treatment of [[type 2 diabetes]] in combination with diet and exercise. It is also approved in the United States for the reduction of [[major adverse cardiovascular events]] in adults with type 2 diabetes who have established [[cardiovascular disease]] or multiple cardiovascular risk factors. It is a once-weekly injection.


<!--T:8-->
The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.
The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.


<!--T:9-->
<!-- History and culture -->
<!-- History and culture -->
It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. [[glucagon-like peptide-1|GLP-1]] is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The [[Food and Drug Administration]] (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2021, it was the 70th most commonly prescribed medication in the United States, with more than 9{{nbsp}}million prescriptions.
It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. [[glucagon-like peptide-1|GLP-1]] is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The [[Food and Drug Administration]] (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2021, it was the 70th most commonly prescribed medication in the United States, with more than 9{{nbsp}}million prescriptions.


==Medical uses==
==Medical uses== <!--T:10-->
The compound is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular [[metformin]], [[sulfonylurea]]s, [[thiazolidinedione]]s, and [[insulin]] taken concomitantly with meals.
The compound is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular [[metformin]], [[sulfonylurea]]s, [[thiazolidinedione]]s, and [[insulin]] taken concomitantly with meals.


<!--T:11-->
The medication's phase 3 clinical trial program demonstrated reductions in hemoglobin A1c of approximately 1% with the 0.75&nbsp;mg and 1.5&nbsp;mg doses of the medication, along with approximately 5 pounds of weight loss on average. The higher 3.0&nbsp;mg and 4.5&nbsp;mg doses that were approved in 2020 demonstrated hemoglobin A1c reductions closer to 1.5% and slightly more weight loss.
The medication's phase 3 clinical trial program demonstrated reductions in hemoglobin A1c of approximately 1% with the 0.75&nbsp;mg and 1.5&nbsp;mg doses of the medication, along with approximately 5 pounds of weight loss on average. The higher 3.0&nbsp;mg and 4.5&nbsp;mg doses that were approved in 2020 demonstrated hemoglobin A1c reductions closer to 1.5% and slightly more weight loss.


<!--T:12-->
A 2017 [[meta-analysis]] did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics.
A 2017 [[meta-analysis]] did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics.


==Side effects==
==Side effects== <!--T:13-->
The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]]. Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylurea]]s or [[insulin]]. There is also a potential risk of [[medullary thyroid carcinoma]] associated with the use of the drug.
The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]]. Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylurea]]s or [[insulin]]. There is also a potential risk of [[medullary thyroid carcinoma]] associated with the use of the drug.


==Contraindications==
==Contraindications== <!--T:14-->
The compound is contraindicated in subjects with [[hypersensitivity]] to the [[active ingredient]] or any of the product's components.
The compound is contraindicated in subjects with [[hypersensitivity]] to the [[active ingredient]] or any of the product's components.


<!--T:15-->
People with a personal or family history of [[medullary thyroid cancer]] (MTC) or affected by [[multiple endocrine neoplasia]] type 2 should not take dulaglutide, because it could increase the risk of these cancers.
People with a personal or family history of [[medullary thyroid cancer]] (MTC) or affected by [[multiple endocrine neoplasia]] type 2 should not take dulaglutide, because it could increase the risk of these cancers.


==Mechanism of action==
==Mechanism of action== <!--T:16-->
Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increases insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by [[L cell]]s of the gastrointestinal mucosa in response to a meal.
Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increases insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by [[L cell]]s of the gastrointestinal mucosa in response to a meal.


==History==
==History== <!--T:17-->
The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control).
The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control).


<!--T:18-->
The U.S. [[Food and Drug Administration]] (FDA) approved dulaglutide with a [[Risk Evaluation and Mitigation Strategies|Risk Evaluation and Mitigation Strategy]] (REMS), and granted the approval of Trulicity to [[Eli Lilly and Company]]. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of [[medullary thyroid carcinoma]]  associated with the drug.
The U.S. [[Food and Drug Administration]] (FDA) approved dulaglutide with a [[Risk Evaluation and Mitigation Strategies|Risk Evaluation and Mitigation Strategy]] (REMS), and granted the approval of Trulicity to [[Eli Lilly and Company]]. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of [[medullary thyroid carcinoma]]  associated with the drug.


<!--T:19-->
In 2020, the FDA approved two higher doses of the medication, 3.0&nbsp;mg and 4.5&nbsp;mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.
In 2020, the FDA approved two higher doses of the medication, 3.0&nbsp;mg and 4.5&nbsp;mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.


== Further reading ==
== Further reading == <!--T:20-->
* {{cite journal | vauthors = Scott LJ | title = Dulaglutide: A Review in Type 2 Diabetes | journal = Drugs | volume = 80 | issue = 2 | pages = 197–208 | date = February 2020 | pmid = 32002850 | doi = 10.1007/s40265-020-01260-9 | s2cid = 210954338 }}
* {{cite journal | vauthors = Scott LJ | title = Dulaglutide: A Review in Type 2 Diabetes | journal = Drugs | volume = 80 | issue = 2 | pages = 197–208 | date = February 2020 | pmid = 32002850 | doi = 10.1007/s40265-020-01260-9 | s2cid = 210954338 }}
* {{cite journal | vauthors = Edwards KL, Minze MG | title = Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | journal = Core Evidence | volume = 10 | pages = 11–21 | date = 2015 | pmid = 25657615 | pmc = 4295897 | doi = 10.2147/CE.S55944 | doi-access = free }}
* {{cite journal | vauthors = Edwards KL, Minze MG | title = Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | journal = Core Evidence | volume = 10 | pages = 11–21 | date = 2015 | pmid = 25657615 | pmc = 4295897 | doi = 10.2147/CE.S55944 | doi-access = free }}
* {{cite journal | vauthors = Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J | title = A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | journal = Diabetes Therapy | volume = 10 | issue = 1 | pages = 5–19 | date = February 2019 | pmid = 30506340 | pmc = 6349277 | doi = 10.1007/s13300-018-0535-9 }}
* {{cite journal | vauthors = Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J | title = A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes | journal = Diabetes Therapy | volume = 10 | issue = 1 | pages = 5–19 | date = February 2019 | pmid = 30506340 | pmc = 6349277 | doi = 10.1007/s13300-018-0535-9 }}


<!--T:21-->
{{Oral hypoglycemics and insulin analogs|state=expanded}}
{{Oral hypoglycemics and insulin analogs|state=expanded}}
{{Portal bar | Medicine}}
{{Portal bar | Medicine}}


<!--T:22-->
{{二次利用|date=7 February 2024}}
{{二次利用|date=7 February 2024}}
[[Category:Drugs developed by Eli Lilly and Company]]
[[Category:Drugs developed by Eli Lilly and Company]]
[[Category:GLP-1 receptor agonists]]
[[Category:GLP-1 receptor agonists]]
[[Category:Peptide therapeutics]]
[[Category:Peptide therapeutics]]
</translate>

Latest revision as of 10:29, 12 February 2024

Other languages:
Medication > Diabetes medication > GLP-1 receptor agonist > Dulaglutide
Dulaglutide
Autoinjector with Trulicity by Lilly
Clinical data
Trade namesTrulicity, others
AHFS/Drugs.comMonograph
MedlinePlusa614047
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous
Drug classIncretin mimetics
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2646H4044N704O836S18
Molar mass59670.63 g·mol−1

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.

The most common side effects are nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.

It is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The Food and Drug Administration (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2021, it was the 70th most commonly prescribed medication in the United States, with more than 9 million prescriptions.

Medical uses

The compound is indicated for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular metformin, sulfonylureas, thiazolidinediones, and insulin taken concomitantly with meals.

The medication's phase 3 clinical trial program demonstrated reductions in hemoglobin A1c of approximately 1% with the 0.75 mg and 1.5 mg doses of the medication, along with approximately 5 pounds of weight loss on average. The higher 3.0 mg and 4.5 mg doses that were approved in 2020 demonstrated hemoglobin A1c reductions closer to 1.5% and slightly more weight loss.

A 2017 meta-analysis did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics.

Side effects

The most common side effects include gastrointestinal disorders, such as dyspepsia, decreased appetite, nausea, vomiting, abdominal pain, diarrhea. Some patients may experience serious adverse reactions: acute pancreatitis (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), hypoglycemia, renal impairment (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with sulfonylureas or insulin. There is also a potential risk of medullary thyroid carcinoma associated with the use of the drug.

Contraindications

The compound is contraindicated in subjects with hypersensitivity to the active ingredient or any of the product's components.

People with a personal or family history of medullary thyroid cancer (MTC) or affected by multiple endocrine neoplasia type 2 should not take dulaglutide, because it could increase the risk of these cancers.

Mechanism of action

Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increases insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, as glucagon is known to be inappropriately elevated in diabetic patients. GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal.

History

The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control).

The U.S. Food and Drug Administration (FDA) approved dulaglutide with a Risk Evaluation and Mitigation Strategy (REMS), and granted the approval of Trulicity to Eli Lilly and Company. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with the drug.

In 2020, the FDA approved two higher doses of the medication, 3.0 mg and 4.5 mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.

Further reading

  • Scott LJ (February 2020). "Dulaglutide: A Review in Type 2 Diabetes". Drugs. 80 (2): 197–208. doi:10.1007/s40265-020-01260-9. PMID 32002850. S2CID 210954338.
  • Edwards KL, Minze MG (2015). "Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes". Core Evidence. 10: 11–21. doi:10.2147/CE.S55944. PMC 4295897. PMID 25657615.
  • Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J (February 2019). "A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes". Diabetes Therapy. 10 (1): 5–19. doi:10.1007/s13300-018-0535-9. PMC 6349277. PMID 30506340.
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Dulaglutide&oldid=113599"